Literature DB >> 8651708

Biochemical characterization of the human liver cytochrome P450 arachidonic acid epoxygenase pathway.

D C Zeldin1, C R Moomaw, N Jesse, K B Tomer, J Beetham, B D Hammock, S Wu.   

Abstract

Human liver microsomal fractions metabolized arachidonic acid in the presence of NADPH yielding epoxyeicosatrienoic acids and their hydration products, dihydroxyeicosatrienoic acids, as the principal reaction products. Inhibition studies using polyclonal antibodies prepared against recombinant CYP2C8, an abundant human liver cytochrome P450 epoxygenase, demonstrated 85-90% inhibition of arachidonic acid epoxide formation. Both epoxyeicosatrienoic acids and dihydroxyeicosatrienoic acids were detected in large amounts in human liver using gas chromatography/mass spectrometry. Chiral analysis of the endogenous liver epoxides demonstrated a preference for the 14(R),15(S)-, 11(R),12(S)-, and 8(S),9(R)-epoxyeicosatrienoic acid enantiomers. Importantly, the chirality of liver epoxyeicosatrienoic acids matched that previously reported for recombinant CYP2C8 (Zeldin et al. (1995) Arch. Biochem. Biophys. 322, 76-86). Incubations of both human liver cytosolic and microsomal fractions with synthetic epoxyeicosatrienoic acids revealed a 10-fold higher rate of dihydroxyeicosatrienoic acid formation with cytosolic relative to microsomal fractions. Recombinant human liver cytosolic epoxide hydrolase rapidly and regioselectively hydrated epoxyeicosatrienoic acids. We conclude, based on these data, that CYP2C8 is one of the primary, constitutive hepatic arachidonic acid epoxygenases responsible for formation of epoxyeicosatrienoic acids and that cytosolic epoxide hydrolase is the principal liver enzyme which forms the dihydroxyeicosatrienoic acids. We speculate that these biologically active eicosanoids may be important in maintaining homeostasis in the liver.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8651708     DOI: 10.1006/abbi.1996.0229

Source DB:  PubMed          Journal:  Arch Biochem Biophys        ISSN: 0003-9861            Impact factor:   4.013


  31 in total

1.  Soluble epoxide hydrolase as an anti-inflammatory target of the thrombolytic stroke drug SMTP-7.

Authors:  Naoki Matsumoto; Eriko Suzuki; Makoto Ishikawa; Takumi Shirafuji; Keiji Hasumi
Journal:  J Biol Chem       Date:  2014-10-31       Impact factor: 5.157

Review 2.  Human Family 1-4 cytochrome P450 enzymes involved in the metabolic activation of xenobiotic and physiological chemicals: an update.

Authors:  Slobodan P Rendic; F Peter Guengerich
Journal:  Arch Toxicol       Date:  2021-01-18       Impact factor: 5.153

3.  Genetic polymorphisms of CYP2C8 in the Czech Republic.

Authors:  Kristina Pechandova; Helena Buzkova; Olga Matouskova; Frantisek Perlik; Ondrej Slanar
Journal:  Genet Test Mol Biomarkers       Date:  2012-02-07

4.  Analysis of epoxyeicosatrienoic acids by chiral liquid chromatography/electron capture atmospheric pressure chemical ionization mass spectrometry using [13C]-analog internal standards.

Authors:  Clementina Mesaros; Seon Hwa Lee; Ian A Blair
Journal:  Rapid Commun Mass Spectrom       Date:  2010-11-30       Impact factor: 2.419

Review 5.  Interethnic and intraethnic variability of CYP2C8 and CYP2C9 polymorphisms in healthy individuals.

Authors:  Elena García-Martín; Carmen Martínez; José M Ladero; José A G Agúndez
Journal:  Mol Diagn Ther       Date:  2006       Impact factor: 4.074

6.  Human cytochrome P450 oxidation of 5-hydroxythalidomide and pomalidomide, an amino analogue of thalidomide.

Authors:  Goutam Chowdhury; Norio Shibata; Hiroshi Yamazaki; F Peter Guengerich
Journal:  Chem Res Toxicol       Date:  2013-12-24       Impact factor: 3.739

Review 7.  Epoxides and soluble epoxide hydrolase in cardiovascular physiology.

Authors:  John D Imig
Journal:  Physiol Rev       Date:  2012-01       Impact factor: 37.312

8.  Stereoselective epoxidation of the last double bond of polyunsaturated fatty acids by human cytochromes P450.

Authors:  Danièle Lucas; Sophie Goulitquer; Jan Marienhagen; Maude Fer; Yvonne Dreano; Ulrich Schwaneberg; Yolande Amet; Laurent Corcos
Journal:  J Lipid Res       Date:  2009-11-25       Impact factor: 5.922

9.  Beneficial effects of soluble epoxide hydrolase inhibitors in myocardial infarction model: Insight gained using metabolomic approaches.

Authors:  Ning Li; Jun-Yan Liu; Valeriy Timofeyev; Hong Qiu; Sung Hee Hwang; Dipika Tuteja; Ling Lu; Jun Yang; Hideki Mochida; Reginald Low; Bruce D Hammock; Nipavan Chiamvimonvat
Journal:  J Mol Cell Cardiol       Date:  2009-08-28       Impact factor: 5.000

10.  Role of cytochrome P450 2C8 and 2J2 genotypes in calcineurin inhibitor-induced chronic kidney disease.

Authors:  Helen E Smith; J P Jones; Thomas F Kalhorn; Federico M Farin; Patricia L Stapleton; Connie L Davis; James D Perkins; David K Blough; Mary F Hebert; Kenneth E Thummel; Rheem A Totah
Journal:  Pharmacogenet Genomics       Date:  2008-11       Impact factor: 2.089

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.